Biotech Investors: Mark Your 2005 Calendars
Successful biotech investors stay on top of the calendar, because they need to be proactive about clinical data and Food and Drug Administration action dates. Regular readers have had an insatiable appetite for previous biotech catalyst calendars, so here's my latest for 2005. It's not comprehensive, and some of the dates are approximations, but this should give biotech investors a good road map for the upcoming year.
FDA Approvals/Filing Dates
American Pharmaceutical Partners (APPX): Abraxane, breast cancer, Jan. 8, 2005;
Cyberonics (CYBX): VNS Therapy System, depression, Jan. 31, 2005;
Discovery Labs (DSCO): Surfaxin, respiratory distress syndrome (pediatrics), Feb. 13, 2005;Millennium Pharmaceuticals (MLNM): Velcade, second-line multiple myeloma, March 29, 2005; Celgene (CELG): Revlimid, FDA filing for myelodysplastic syndrome (5 q minus), first quarter 2005. Revlimid, multiple myeloma phase III, second half 2005; Cephalon (CEPH): Nuvigil, narcolepsy, sleep apnea, shift work sleep disorder FDA filing, first quarter 2005; Amylin Pharmaceuticals (AMLN): Symlin, diabetes, March 20, 2005. Exenatide, diabetes, April 30, 2005; Adolor (ADLR): Entereg, post-operative ileus, April 25, 2005; ImClone Systems (IMCL): Erbitux, FDA filing for head and neck cancer, second quarter 2005.
Clinical DataAphton (APHT): Insegia, gastrointestinal cancer phase III, first quarter 2005; Genaera (GENR): Squalamine, age-related macular degeneration phase II, first quarter 2005. Squalamine, age-related macular degeneration, phase III, year-end 2005; Corgentech (CGTK): E2F Decoy, coronary artery bypass graft failure phase III, early 2005; Cell Therapeutics (CTIC): Xyotax, non-small-cell lung cancer phase III, first quarter 2005; Axonyx (AXYX): Phenserine, Alzheimer's disease phase II, first quarter 2005; Encysive Pharmaceuticals (ENCY): Thelin, pulmonary arterial hypertension phase III, February 2005; Biogen Idec (BIIB), Elan (ELN): Tysabri, two-year multiple sclerosis data, first half 2005. Tysabri, Crohn's disease phase III (induction), rheumatoid arthritis phase II, midyear 2005; Antigenics (AGEN): Oncophage, renal cell cancer phase III; second quarter 2005; CV Therapeutics (CVTX): Ranexa, angina phase III, second quarter 2005; Transkaryotic Therapies (TKTX): I2S, Hunter Syndrome phase III, June 2005. Dynepo, oncology phase III, first half 2005; Onyx Pharmaceuticals (ONXX): BAY 43-9006, renal cancer phase III interim analysis, first half 2005.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV